[Immunophenotypic changes after central recurrence in a case of Ph positive B-ALL receiving sequential infusion of anti-CD22 and anti-CD19 CAR-T therapy].
作者信息
Mao X, He C, Liu S Y, Wang C Y, Zhu L, Wang N, Xiao M, Zhou J F, Xiao Y
机构信息
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):246. doi: 10.3760/cma.j.issn.0253-2727.2019.03.017.
Abstract
摘要
相似文献
1
[Immunophenotypic changes after central recurrence in a case of Ph positive B-ALL receiving sequential infusion of anti-CD22 and anti-CD19 CAR-T therapy].[1例接受抗CD22和抗CD19嵌合抗原受体T细胞（CAR-T）序贯输注治疗的Ph阳性B淋巴细胞白血病患者中枢复发后的免疫表型变化]
Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):246. doi: 10.3760/cma.j.issn.0253-2727.2019.03.017.
2
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.CD22 靶向 CAR T 细胞可诱导对 CD19 靶向 CAR 免疫疗法初治或耐药的 B-ALL 缓解。
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
3
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.序贯抗 CD19、22 和 20 自体嵌合抗原受体 T 细胞（CAR-T）治疗复发难治性伯基特淋巴瘤患儿：病例报告及文献复习。
J Cancer Res Clin Oncol. 2020 Jun;146(6):1575-1582. doi: 10.1007/s00432-020-03198-7. Epub 2020 Mar 28.
4
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.接受抗 CD19 和抗 CD22 CAR T 细胞治疗弥漫性大 B 细胞淋巴瘤的患者发生严重早期乙型肝炎病毒再激活。
J Immunother Cancer. 2019 Nov 21;7(1):315. doi: 10.1186/s40425-019-0790-y.
5
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.单倍体相合 CD19/CD22 双特异性 CAR-T 细胞在单倍体相合造血干细胞移植后复发难治性成人 B-ALL 患者中诱导 MRD 阴性缓解。
J Hematol Oncol. 2019 Jun 10;12(1):57. doi: 10.1186/s13045-019-0741-6.
6
[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].CD19嵌合抗原受体T细胞治疗异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者的疗效
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1040-1045. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.008.
7
Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.aT19 细胞序贯治疗可产生记忆型 CAR-T 细胞，并延长 Raji-B-NDG 小鼠的生存期。
Cancer Lett. 2020 Jan 28;469:162-172. doi: 10.1016/j.canlet.2019.10.022. Epub 2019 Oct 18.
8
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
9
Erratum: Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum].勘误：抗CD22和抗CD19嵌合抗原受体T细胞序贯输注治疗1例CART细胞和单倍体造血干细胞移植治疗后复发的儿童Ph样B淋巴细胞白血病患者：病例报告及文献复习[勘误]
Onco Targets Ther. 2020 Apr 9;13:3045. doi: 10.2147/OTT.S255629. eCollection 2020.
10
[Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].CD19嵌合抗原受体T细胞治疗复发/难治性B细胞淋巴瘤疗效不佳的因素分析
Zhonghua Yi Xue Za Zhi. 2020 Mar 3;100(8):593-598. doi: 10.3760/cma.j.issn.0376-2491.2020.08.006.
引用本文的文献
1
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss.三价BAFF嵌合抗原受体T细胞可消除表达BAFFR且丧失CD19抗原的B细胞恶性肿瘤。
Cancer Cell Int. 2021 Apr 17;21(1):223. doi: 10.1186/s12935-021-01923-x.
Zotero 插件